Abstract
The risk of developing Alzheimer’s disease (AD) is tied most closely to age and appears to follow Gompertzian kinetics. However, specific genetic factors are also linked closely to AD, and the apolipoprotein E (APOE) genotype accounts for as much of 50% of the attributable risk for AD in many populations. This paper reviews the onset, diagnosis, and epidemiology of AD, specifically with regard to the APOE genotype and the interaction of the genotype with age.
References
Arendt T. (2001) Disturbance of neuronal plasticity is a critical pathogenetic event in Alzheimer’s disease. Int. J. Dev. Neurosci. 19, 231–245.
Ashford J. W., Kindy M. S., Shih W.-J., Cool C., Aleem B., Cobb L., et al. Clinical onset of Alzheimer’s disease (AD) is earlier in patients with an APOE ε4 allele. Annual Meeting, Society for Neuroscience, Orlando, FL, 723.4, 2002.
Ashford J. W. and Jarvik L. (1985) Alzheimer’s disease: does neuron plasticity predispose to axonal neurofibrillary degeneration? N. Engl. J. Med. 313, 388–389.
Ashford J. W. and Mortimer J. A. (2002) Non-familial Alzheimer’s disease is mainly due to genetic factors. J. Alzheimer’s Dis. 4, 169–177.
Ashford J. W., Schmitt F., and Kumar V. (1998a) Diagnosis of Alzheimer’s disease, in Advances in the Diagnosis and Treatment of Alzheimer’s Disease, Kumar, V., and Eisdorfer, C., eds., Springer, New York, pp. 111–151.
Ashford J. W., Mattson M., and Kumar V. (1998b) Neurobiological systems disrupted by Alzheimer’s disease and molecular neurobiological theories of vulnerability, in Advances in the Diagnosis and Treatment of Alzheimer’s Disease, Kumar, V., and Eisdorfer, C., eds., Springer, New York, pp. 53–89.
Ashford J. W., Shan M., Butler S., Rajesekar A., and Schmitt F. (1995) Temporal quantification of Alzheimer’s disease severity: ‘Time Index Model’. Dementia 6, 269–280.
Ashford J. W., Shih W.-J., Coupal J., Shetty R., Schneider A., Cool C., et al. (2000) Single SPECT measures of cerebral cortical perfusion reflect “Time-Index” estimation of dementia severity in Alzheimer’s disease. J. Nuclear Med. 41, 57–64.
Blacker D., Haines J. L., Rodes L., Terwedow H., Go R. C. P., Harrell, L. E., et al. (1997) ApoE-4 and age at onset of Alzheimer’s disease: The NIMH genetics initiative. Neurology 48, 139–147.
Blessed G., Tomlinson B. E., Roth M. (1968) The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br. J. Psychiatry 114, 797–811.
Breitner J. C. S., Wyse B. W., Anthony J. C., Welsh-Bohmer K., Steffens D. C., Norton M. C., et al. (1999) APOE-ε4 count predicts age when prevalence of AD increases, then declines: The Cache County Study. Neurology 53, 321–331.
Codemo A., Corti M. C., Mazzetto G., Varotto S., Cortella I., Crepaldi G., and Gabelli C. (2000) Education, APOE status and cognitive impairment in the elderly: an epidemiological study in a rural setting. Neurobiol. Aging 21, S246.
Corbo R. M. and Scacchi R. (1999) Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a ‘thrify’ allele? Ann. Hum. Genet. 63, 301–310.
Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921–923.
Dean C., Leakey M. G, Reid D., Schrenk F., Schwartz G. T., Stringer C., and Walker A. (2001) Growth processes in teeth distinguish modern humans from Homo erectus and earlier hominins. Nature 414, 628–631.
Evans D. A., Beckett L. A., Field T. S., Feng L., Albert M. S., Bennett D. A., et al. (1997) Apolipoprotein E ε4 and incidence of Alzheimer disease in a community population of older persons. JAMA 277, 822–824).
Farrer L. A., Cupples L. A., Haines J. L., Hyman B., Kukull W. A., Mayeux R., et al. (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis. JAMA 278, 1349–1356.
Folstein M. F., Folstein S. E., and McCugh P. R. (1975) “Mini-Mental State”: A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189–198.
Frisoni G. B., Louhiha J., Geroldi C., and Trabucchi M. (2001) Longevity and the epsilon 2 allele of apolipoprotein E: the Finnish Centenarians Study. J. Gerontol. A Biol. Sci. Med. Sci. 56, M75-M78.
Fullerton S. M., Clark A. G., Weiss K. M., Nickerson D. A., Taylor S. L., Stengard J. H., et al. (2000) Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism. Am. J. Hum. Genet. 67, 881–900.
Ganguli M., Chandra V., Kamboh I., Johnston J. M., Dodge H. H., Thelma B. K., et al. (2000) Apolipoprotein E polymorphism and Alzheimer’s disease: the Indo-US Cross-National Dementia Study, Arch. Neurol. 57, 824–830.
Guo Z., Fratiglioni L., Viitanen M., Lannfelt L., Basun, H., Fastbom J., and Winblad B. (2001) Apolipoprotein E genotypes and the incidence of Alzheimer’s disease among persons aged 75 years and older: variation by use of anti-hypertensive medication? Am. J. Epidemiol. 153, 225–231.
Hendrie H. C., Ogunniyi A., Hall K. S., Baiyewu O., Unverzagt F. W., Gureje O., et al. (2001) Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA 285, 739–747.
Hirsch H. R. (1994) Can an improved environment cause maximum lifespan to decrease? Comments of lifespan criteria and longitudinal Gompertzian analysis. Exp. Gerontol. 29, 119–137.
Hirsch H. R. (1995) Do intersections of mortality-rate and survival functions have significance? Exp. Gerontol. 30, 147–167.
Jarvik G. P., Wijsman E. M., Kukull W. A., Schellenberg G. D., Yu C., and Larson E. B. (1995) Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer’s disease: a case-control study. Neurology 45, 1092–1096.
Jick H., Zornbert G. L., Jick S. S., Seshadri S., and Drachman D. A. (2000) Statins and the risk of dementia. Lancet 356, 1627–1631.
Koudinov A. R. and Koudinova N. V. (2001) Essential role for cholesterol in synaptic plasticity and neuronal degeneration. FASEB J. 10, 1858–1869.
Lehmann D. J., Williams J., McBroom J., and Smith A. D. (2001) Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer’s disease and to identify high-risk subgroups. Neuroscience 108, 541–554.
Liu H. C., Hong C. J, Wang S. J., Fuh J. L., Wang P. N., Shyu H. Y., and Teng E. L. (1999) ApoE genotype in relation to AD and cholesterol; a study of 2,326 Chinese adults. Neurology 53, 962–966.
Mauch D. H., Nagler K., Schumacher S., Goritz C., Muller E.-C., Otto A., and Pfrieger F. W. (2001) CNS synaptogenesis promoted by glia-derived cholesterol. Science 294, 1354–1357.
Mendiondo M. S., Ashford J. W., Kryscio R. J., Schmitt F. A. (2003) Designing a Brief Alzheimer Screen (BAS). J. Alzheimers Dis. 5, 391–398.
Mesulam M. M. (1999) Neuroplasticity failure in Alzheimer’s disease: bridging the gap between plaques and tangles. Neuron 24, 521–529.
Miech R. A., Breitner J. C., Zandi P. P., Khachaturian A. S., Anthony J. C., Mayer L. (2002) Incidence of AD may decline in the early 90s for men, later for women: The Cache County study. Neurology 58, 209–218.
Myers R. H., Schaefer E. J., Wilson P. W. F., D’Agostino R., Ordovas J. M., Espino A., et al. (1996) Apolipoprotein E ε4 association with dementia in a population-based study: the Framingham Study. Neurology 46, 673–677.
Ohm T. G., Scharnagl H., Marz W., and Bohl J. (1999) Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer’s disease-related lesions. Acta Neuropathol. 98, 273–280.
Oppenheimer S. (2003) The Real Eve: Modern Man’s Journey Out of Africa. Carroll and Graf Publishers, New York.
Perls T. T., Morris J. N., Ooi W. L., and Lipsitz L. A. (1993) The relationship between age, gender and cognitive performance in the very old: the effect of selective survival. J. Am. Geriatr. Soc. 41, 1193–1201.
Petersen R. C., Smith G. E., Waring S. C., Ivnik R. J., Tangalos E. G., and Kokmen E. (1999) Mild cognitive impairment, clinical characterization and outcome. Arch. Neurol. 56, 303–308.
Roses A. D. (1995) Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer’s disease. Ann. Neurol. 38, 6–14.
Roses A. D. (1996) Apolipoprotein E: alleles as risk factors in Alzheimer’s disease. Annu. Rev. Med. 47, 387–400.
Roses A. D. (1997) Apolipoprotein E: a gene with complex biological interactions in the aging brain. Neurobiol Dis. 4, 170–85.
Sacher G. A. (1977) Life table modification and life prolongation, in The Handbook of the Biology of Aging, Finch, C. E., and Hayflick, L., eds., Van Nostrand Reinhold, New York, pp. 582–638.
Saunders A. M., Strittmatter W. J., Schmechel D., St. George-Hyslop P. H., Pericak-Vance M. A., Joo S. H., et al. (1993) Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 43, 1467–1472.
Seshadri S., Drachman D. A., and Lippa C. F. (1995) Apolipoprotein E ε4 allele and the lifetime risk of Alzheimer’s disease: what physicians know, and what they should know. Arch. Neurol. 52, 1074–1079.
Shih W.-J., Ashford J. W., Stipp V., Magoun S. L., Coupal J. J., and Gross K. K. (1999) Consecutive brain SPECT surface three-dimensional displays show progression of cerebral cortical abnormalities in Alzheimer’s disease. Clin. Nuclear Med. 24, 773–777.
Slooter A. J. C., Cruts M., Kalmijn S., Hofman A., Breteler M. M. B., Van Broeckhoven C., and van Duijn C. M. (1998) Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch. Neurol. 55, 964–968.
Strehler B. L. (1977) Time, Cells, and Aging, Academic Press, New York.
Stringer C. (2002) Modern human origins: progress and prospects. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 357, 563–579.
Warwick Daw E., Payami H., Nemens E. J., Nochlin D., Bird T. D., Schellenberg G. D., and Wijsman E. M. (2000) The number of trait loci in late-onset Alzheimer disease. Am. J. Hum. Genet. 66, 196–204.
Winnock M., Letenneur L., Jacqmin-Gadda H., Dallongeville J., Amouyel P., and Dartigues J. F. (2002) Longitudinal analysis of the effect of apolipoprotein E ε4 and education on cognitive performance in elderly subjects: the PAQUID study. J. Neurol. Neurosurg. Psychiatry. 72, 794–797.
Wilson P. W. F., Schaefer E. J., Larson M. G., and Ordovas J. M. (1996) Apolipoprotein E alleles and risk of coronary disease. Arterioscler. Thromb. Vasc. Biol. 16, 1250–1255.
Wolozin B., Kellman W., Ruosseau P., Celesia G. G., and Siegal G. (2000) Decreased prevalence of Alzheimer’s disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439–1443.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ashford, J.W. APOE genotype effects on alzheimer’s disease onset and epidemiology. J Mol Neurosci 23, 157–165 (2004). https://doi.org/10.1385/JMN:23:3:157
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/JMN:23:3:157